Annual Report 2024

Annual Report 2024

Peer group selection

We have rapidly evolved and will continue to evolve into a fully integrated immunology company with a strong presence globally. To thrive and continue building the organization, we need executive and nonexecutive talent with a deep understanding of the global market in which we operate. We therefore compete for global talent. This is why we have established a global peer group focused on six key criteria that reflect the companies we benchmark against in attracting and retaining top talent.

In connection with the benchmark exercise for 2025 remuneration ahead of setting fixed and variable pay levels, the following criteria were used for the first time in the third quarter of 2024 to select the new global peer group (the Peer Group).

Compared to the European and Global peer groups used for the determine of the remuneration until 2024, the 2025 Peer Group consists of 15 companies. We deem a minimum of 15 companies appropriate, because (i) our industry tends to evolve quickly, with companies emerging and disappearing (due to mergers or otherwise) relatively often, and (ii) we deem it relevant to have a certain consistency in the companies comprising our peer group over the longer term.

If there are not 15 companies meeting each of the criteria, we will include in our reference group all companies that meet the criteria, and supplement with companies that meet all but one criterion. The least relevant criterion will be dropped first, in the order as displayed below (from most to least relevant).

Peer group selection – Criteria

Selection Criterion
in order of relevance

 

Range of Peers based on Criterion

 

Relevance of criterion

1. Sector

 

Biopharmaceutical companies, excluding diagnostics and animal health companies

 

Biopharmaceutical companies have characteristic pay and incentive structures compared to other industries.
Within the biopharmaceutical industry, excluding diagnostics and animal health companies is appropriate because the talent focus of such companies is different and therefore they are not typically our competitors for talent. In addition, their pay structures tend to differ from those in our industry making these less relevant comparators.

2. Listing location

 

Listed on a major US Stock Exchange

 

Being listed on a major US stock exchange brings additional complexity, expertise requirements and potential liabilities to company officers and directors, which is typically reflected in a different pay structure of executives and board members serving on US listed companies, versus companies without a US listing. Our benchmark exercise shows that having a listing on a major US stock exchange tends to have a more significant relevance for pay structure applied by companies than does location of headquarters, which is why we do not apply a ‘location of headquarters’ filter.

3. Innovation focus

 

At least 25% of revenue is spent on R&D

 

Innovation focused, R&D driven companies tend to have a typical remuneration structure which differs from companies who focus on commercializing external innovations.
To ensure we continue to be able to compete with other innovators, we limit our peer group selection to other companies who continue to significantly invest in their R&D activities.

4. Global reach

 

Generates product revenues both within and outside the US

 

Leading commercial operations both inside and outside the United States puts unique demands on the skills and expertise of key individuals, in addition to the strain of splitting their time and efforts across continents. For this reason, we compare pay practices to other global companies instead of companies with mostly local activities.

5. Revenue

 

1/4 – 4x of our annual revenue

 

We compare ourselves to organizations that also have significant product revenues, as a reflection of overall size and complexity of the organization. Using a relatively wide range for this metric is appropriate to ensure we include relevant peers while ensuring a level of stability in the peer group over time. In setting the range, we also considered the rapid development in our own revenues since our first year of product commercialization (2023) and our internal revenue projections for the immediate future.

6. Market Cap

 

1/4 – 4x our market cap (based on 30 day average closing price)

 

Whereas market cap can give some indication of overall size and complexity of comparator organizations, we also recognize that companies in our sector tend to have volatile stock prices and market cap can vary significantly even throughout a given calendar year.1)
Using a relatively wide range for this metric is appropriate to ensure we include relevant peers while ensuring a level of stability in the peer group year-over-year.
By going as low as 1/4x our value and as high as 4x our value, we aim to ensure that we are not positioning ourselves on either end of the peer group for this metric, to avoid establishing a peer group that is considered aspirational.
Finally, given that market cap is influenced by a range of factors that do not necessarily correlate to the organization’s size or complexity or talent needs, we deem this the least relevant filter. If we are unable to reach our minimum of 15 peer companies meeting all selection criteria, we will include companies who meet all other criteria and are closest to our market cap criterion (but no more than 2x the high end of our range) in order to make up the 15. If we cannot make up to 15 applying this modified filter, we will include companies who are outside of but close to our revenue filter limits.

1)

As at March 17, 2025, the delta between our 52-week high and low was approximately 104%, https://live.euronext.com/nl/product/equities/NL0010832176-XBRU.

Peer group selection – Companies

Company Name

 

Country of Headquarters

Alnylam Pharmaceuticals, Inc.

 

USA

Amicus Therapeutics, Inc.

 

USA

Ascendis Pharma A/S

 

Denmark

BeiGene, Ltd.

 

Cayman Islands

Biogen Inc.

 

USA

BioMarin Pharmaceutical Inc.

 

USA

BioNTech SE

 

Germany

Blueprint Medicines Corporation

 

USA

Genmab SE

 

Denmark

Incyte Corporation

 

USA

Insmed Inc.

 

USA

Jazz Pharmaceuticals plc

 

Ireland

Moderna, Inc.

 

USA

Sarepta Therapeutics, Inc.

 

USA

Ultragenyx Pharmaceutical Inc.

 

USA